Maternal obesity negatively impacts the placenta, being associated with increased inflammation, decreased mitochondrial respiration, decreased expression of brain-derived neurotrophic factor (BDNF), and its receptor, tropomyosin receptor kinase B (TRKB). TRKB induction by 7,8-dihydroxyflavone (7,8-DHF) improves energy expenditure in an obesity animal model. We hypothesized that TRKB activation would improve mitochondrial respiration in trophoblasts from placentas of obese women. Placentas were collected from lean (pre-pregnancy BMI < 25) and obese (pre-pregnancy BMI > 30) women at term following cesarean section delivery without labor. Cytotrophoblasts were isolated and plated, permitting syncytialization. At 72 hours, syncytiotrophoblasts (STs) were treated for 1 hour with 7,8-DHF (10 nM–10 M), TRKB antagonists (ANA-12 (10 nM–1 M), Cyclotraxin B (1 nM–1M)), or vehicle. Mitochondrial respiration was measured using the XF24 Extracellular Flux Analyzer. TRKB, MAPK, and PGC1α were measured using Western blotting. Maternal obesity was associated with decreased mitochondrial respiration in STs; however, 7,8-DHF increased basal, ATP-coupled, maximal, spare capacity, and nonmitochondrial respiration. A 10 μM dose of 7,8-DHF reduced spare capacity in STs from lean women, with no effect on other respiration parameters. 7,8-DHF had no effect on TRKB phosphorylation; however, there was a concentration-dependent decrease of p38 MAPK phosphorylation and increase of PGC1α in STs from obese, but not in lean women. TRKB antagonism attenuated ATP-coupled respiration, maximal respiration, and spare capacity in STs from lean and obese women. 7,8-DHF improves mitochondrial respiration in STs from obese women, suggesting that the obese phenotype in the placenta can be rescued by TRKB activation.
FlegalKMKruszon-MoranDCarrollMDFryarCDOgdenCL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284–2291.
2.
BodnarLMCatovJMKlebanoffMANessRBRobertsJM. Prepregnancy body mass index and the occurrence of severe hypertensive disorders of pregnancy. Epidemiology. 2007;18(2):234–239.
3.
ChuSYCallaghanWMKimSY. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care. 2007;30(8):2070–2076.
4.
O’BrienTERayJGChanWS. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology. 2003;14(3):368–374.
5.
ChuSYKimSYLauJ. Maternal obesity and risk of stillbirth: a metaanalysis. Am J Obstet Gynecol. 2007;197(3):223–228.
6.
VasudevanCRenfrewMMcGuireW. Fetal and perinatal consequences of maternal obesity. Arch Dis Child Fetal Neonatal Ed. 2011;96(5):F378–F382.
7.
ReeceEA. Obesity, diabetes, and links to congenital defects: a review of the evidence and recommendations for intervention. J Matern Fetal Neonatal Med. 2008;21(3):173–180.
8.
CarterAMEndersAC. Comparative aspects of trophoblast development and placentation. Reprod Biol Endocrinol. 2004;2:46.
SoleymanlouNJurisicaINevoO. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinolo Metab. 2005;90(7):4299–4308.
11.
AyeILLagerSRamirezVI. Increasing maternal body mass index is associated with systemic inflammation in the mother and the activation of distinct placental inflammatory pathways. Biol Reprod. 2014;90(6):129.
12.
MeleJMuralimanoharanSMaloyanAMyattL. Impaired mitochondrial function in human placenta with increased maternal adiposity. Am J Physiol Endocrinol Metab. 2014;307(5):E419–E425.
13.
MuralimanoharanSGuoCMyattLMaloyanA. Sexual dimorphism in miR-210 expression and mitochondrial dysfunction in the placenta with maternal obesity. Int J Obes.(Load). 2015;39(8):1274–1281.
14.
BarkerDJ. The effect of nutrition of the fetus and neonate on cardiovascular disease in adult life. Proc Nutr Soc. 1992;51(2):135–144.
15.
BarkerDJ. Intrauterine programming of coronary heart disease and stroke. Acta Paediatr Suppl. 1997;423:178–182; discussion 183.
16.
BarkerDJGluckmanPDRobinsonJS. Conference report: fetal origins of adult disease—report of the First International Study Group, Sydney, 29-30 October 1994. Placenta. 1995;16(3):317–320.
17.
ChallisJRSlobodaDMatthewsSG. The fetal placental hypothalamic-pituitary-adrenal (HPA) axis, parturition and post natal health. Mol Cell Endocrinol. 2001;185(1-2):135–144.
18.
PhillipsDIJonesA. Fetal programming of autonomic and HPA function: do people who were small babies have enhanced stress responses?J Physiol. 2006;572(pt 1):45–50.
19.
XiongFZhangL. Role of the hypothalamic-pituitary-adrenal axis in developmental programming of health and disease. Front Neuroendocrinol. 2013;34(1):27–46.
20.
RiveraHMChristiansenKJSullivanEL. The role of maternal obesity in the risk of neuropsychiatric disorders. Front Neurosci. 2015;9:194.
21.
SasakiAShinkawaOYoshinagaK. Placental corticotropin-releasing hormone may be a stimulator of maternal pituitary adrenocorticotropic hormone secretion in humans. J Clin Invest. 1989;84(6):1997–2001.
22.
OdagiriESherrellBJMountCDNicholsonWEOrthDN. Human placental immunoreactive corticotropin, lipotropin, and beta-endorphin: evidence for a common precursor. Proc Nati Acad Sci U S A. 1979;76(4):2027–2031.
23.
RamamoorthySLeibachFHMaheshVBGanapathyV. Active transport of dopamine in human placental brush-border membrane vesicles. Am J Physio. 1992;262(5 pt 1):C1189–C1196.
24.
BonninAGoedenNChenK. A transient placental source of serotonin for the fetal forebrain. Nature. 2011;472(7343):347–350.
25.
BonninALevittP. Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain. Neuroscience. 2011;197:1–7.
26.
WuXXieCZhangYFanZYinYBlachierF. Glutamate-glutamine cycle and exchange in the placenta-fetus unit during late pregnancy. Amino Acids. 2015;47(1):45–53.
27.
GarcesMFSanchezETorres-SierraAL. Brain-derived neurotrophic factor is expressed in rat and human placenta and its serum levels are similarly regulated throughout pregnancy in both species. Clin Endocrinol (Oxf). 2014;81(1):141–151.
28.
PrinceCSMaloyanAMyattL. Maternal obesity alters brain derived neurotrophic factor (BDNF) signaling in the placenta in a sexually dimorphic manner. Placenta. 2017;49:55–63.
29.
PhillipsHSHainsJMArmaniniMLarameeGRJohnsonSAWinslowJW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron. 1991;7(5):695–702.
30.
YoshidaTIshikawaMNiitsuT. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One. 2012;7(8):e42676.
31.
MouZHydeTMLipskaBK. Human obesity associated with an intronic SNP in the brain-derived neurotrophic factor locus. Cell Rep. 2015;13(6):1073–1080.
32.
LommatzschMZinglerDSchuhbaeckK. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging. 2005;26(1):115–123.
33.
MarkhamACameronIBainsR. Brain-derived neurotrophic factor-mediated effects on mitochondrial respiratory coupling and neuroprotection share the same molecular signalling pathways. EurJ Neurosci. 2012;35(3):366–374.
34.
MarkhamACameronIFranklinPSpeddingM. BDNF increases rat brain mitochondrial respiratory coupling at complex I, but not complex II. Eur J Neurosci. 2004;20(5):1189–1196.
35.
FujitaKTatsumiKKondohE. Differential expression and the anti-apoptotic effect of human placental neurotrophins and their receptors. Placenta. 2011;32(10):737–744.
36.
LuBNagappanGGuanXNathanPJWrenP. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci. 2013;14(6):401–416.
37.
AnderoRDaviuNEscorihuelaRMNadalRArmarioA. 7,8-dihydroxyflavone, a TRKB receptor agonist, blocks long-term spatial memory impairment caused by immobilization stress in rats. Hippocampus. 2012;22(3):399–408.
38.
JangSWLiuXYepesM. A selective TRKB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci U S A. 2010;107(6):2687–2692.
39.
LiuXObianyoOChanCB. Biochemical and biophysical investigation of the brain-derived neurotrophic factor mimetic 7,8-dihydroxyflavone in the binding and activation of the TRKB receptor. J Biol Chem. 2014;289(40):27571–27584.
40.
AgrawalRTyagiEVergnesLReueKGomez-PinillaF. Coupling energy homeostasis with a mechanism to support plasticity in brain trauma. Biochim Biophys Acta. 2014;1842(4):535–546.
41.
ChanCBTseMCLiuX. Activation of muscular TRKB by its small molecular agonist 7,8-dihydroxyflavone sex-dependently regulates energy metabolism in diet-induced obese mice. Chem Biol. 2015;22(3):355–368.
42.
BaxCMRyderTAMobberleyMATymsASTaylorDLBloxamDL. Ultrastructural changes and immunocytochemical analysis of human placental trophoblast during short-term culture. Placenta. 1989;10(2):179–194.
43.
NichollsDGDarley-UsmarVMWuMJensenPBRogersGWFerrickDA. Bioenergetic profile experiment using C2C12 myoblast cells. J Vis Exp. 2010;(46):e2511. DOI:10.3791/2511.
44.
MuralimanoharanSMaloyanAMeleJGuoCMyattLGMyattL. MIR-210 modulates mitochondrial respiration in placenta with preeclampsia. Placenta. 2012;33(10):816–823.
45.
MaloyanAMeleJMuralimanoharaBMyattL. Measurement of mitochondrial respiration in trophoblast culture. Placenta. 2012;33(5):456–458.
NakagawaTTsuchidaAItakuraY. Brain-derived neurotrophic factor regulates glucose metabolism by modulating energy balance in diabetic mice. Diabetes. 2000;49(3):436–444.
48.
ChenJChuaKWChuaCC. Antioxidant activity of 7,8-dihydroxyflavone provides neuroprotection against glutamate-induced toxicity. Neurosci Lett. 2011;499(3):181–185.
49.
KernieSGLieblDJParadaLF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J. 2000;19(6):1290–1300.
50.
CazorlaMPremontJMannAGirardNKellendonkCRognanD. Identification of a low-molecular weight TRKB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest. 2011;121(5):1846–1857.
51.
CazorlaMJouvenceauARoseC. Cyclotraxin-B, the first highly potent and selective TRKB inhibitor, has anxiolytic properties in mice. PloS One. 2010;5(3):e9777.
52.
KaplanDRMillerFD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol. 2000;10(3):381–391.
53.
ChenLWLinMWHsuCM. Different pathways leading to activation of extracellular signal-regulated kinase and p38 MAP kinase by formyl-methionyl-leucyl-phenylalanine or platelet activating factor in human neutrophils. J Biomed Sci. 2005;12(2):311–319.
54.
YangJMVassilADHaitWN. Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol. 2001;60(4):674–680.
55.
McCubreyJASteelmanLSChappellWH. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–1284.
56.
BarakYNelsonMCOngES. PPAR gamma is required for placental, cardiac, and adipose tissue development. Molr Cell. 1999;4(4):585–595.
57.
SempleRKCrowleyVCSewterCP. Expression of the thermogenic nuclear hormone receptor coactivator PGC-1alpha is reduced in the adipose tissue of morbidly obese subjects. Int J Obes Relat Metab Disord. 2004;28(1):176–179.
58.
CrunkhornSDearieFMantzorosC. Peroxisome proliferator activator receptor gamma coactivator-1 expression is reduced in obesity: potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation. J Biol Chem. 2007;282(21):15439–15450.
59.
KnuttiDKresslerDKralliA. Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor. Proc Natl Acad Sci U S A. 2001;98(17):9713–9718.
60.
FanMRheeJSt-PierreJ. Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. Genes Dev. 2004;18(3):278–289.
61.
LeBleuVSO’ConnellJTGonzalez HerreraKN. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16(10):992–1003.
62.
ValleIAlvarez-BarrientosAArzaELamasSMonsalveM. PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res. 2005;66(3):562–573.
